U.K. AI software developer Brainomix highlighted a study that shows its e-Lung automated CT processing algorithm can stratify patients at risk of idiopathic pulmonary fibrosis (IPF).
The study was an analysis of a completed phase II clinical trial by AstraZeneca of the company’s tralokinumab treatment in patients with idiopathic pulmonary fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool.
e-Lung is powered by what is called the weighted reticulovascular score (WRVS), a biomarker that incorporates reticular opacities and vascular structures in assessments of the lung, Brainomix said. The tool has previously shown that WRVS is more strongly associated with transplant-free survival of IPF patients than standard measurements, according to the company.
The study was published recently in the American Journal of Respiratory and Critical Care Medicine.
